SubHero Banner

Nerlynx® (neratinib) – New indication

February 26, 2020 - Puma Biotechnology announced the FDA approval of Nerlynx (neratinib), in combination with capecitabine for the treatment of adult patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

Download PDF